These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Cacciapuoti A; Halpern J; Mendrick C; Norris C; Patel R; Loebenberg D Antimicrob Agents Chemother; 2006 Jul; 50(7):2587-90. PubMed ID: 16801452 [TBL] [Abstract][Full Text] [Related]
4. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Bowman JC; Abruzzo GK; Anderson JW; Flattery AM; Gill CJ; Pikounis VB; Schmatz DM; Liberator PA; Douglas CM Antimicrob Agents Chemother; 2001 Dec; 45(12):3474-81. PubMed ID: 11709327 [TBL] [Abstract][Full Text] [Related]
5. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ Antimicrob Agents Chemother; 2007 Mar; 51(3):881-7. PubMed ID: 17145783 [TBL] [Abstract][Full Text] [Related]
6. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. Warn PA; Sharp A; Mosquera J; Spickermann J; Schmitt-Hoffmann A; Heep M; Denning DW J Antimicrob Chemother; 2006 Dec; 58(6):1198-207. PubMed ID: 17071636 [TBL] [Abstract][Full Text] [Related]
7. Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy. Plummer R; Bodkin J; Power D; Pantarat N; Bubb WA; Kuchel PW; Sorrell TC Antimicrob Agents Chemother; 2007 Nov; 51(11):4077-84. PubMed ID: 17785514 [TBL] [Abstract][Full Text] [Related]
8. Caspofungin: a major breakthrough in treatment of systemic fungal infections. Agarwal MB; Rathi SA; Ratho N; Subramanian R J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012 [TBL] [Abstract][Full Text] [Related]
9. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. Warn PA; Morrissey G; Morrissey J; Denning DW J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Abruzzo GK; Gill CJ; Flattery AM; Kong L; Leighton C; Smith JG; Pikounis VB; Bartizal K; Rosen H Antimicrob Agents Chemother; 2000 Sep; 44(9):2310-8. PubMed ID: 10952573 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus. Araujo R; Pina-Vaz C; Rodrigues AG Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101 [TBL] [Abstract][Full Text] [Related]
12. The pharmacology and clinical use of caspofungin. Hope WW; Shoham S; Walsh TJ Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):263-74. PubMed ID: 17428155 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Pfaller MA; Marco F; Messer SA; Jones RN Diagn Microbiol Infect Dis; 1998 Apr; 30(4):251-5. PubMed ID: 9582584 [TBL] [Abstract][Full Text] [Related]
20. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp. Peter J; Armstrong D; Lyman CA; Walsh TJ J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]